NYSE:IKT Inhibikase Therapeutics (IKT) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free IKT Stock Alerts $2.19 -0.11 (-4.78%) (As of 02:03 PM ET) Add Compare Share Share Today's Range$2.08▼$2.4450-Day Range$1.72▼$3.2152-Week Range$0.79▼$4.56Volume92,750 shsAverage Volume147,100 shsMarket Capitalization$13.51 millionP/E RatioN/ADividend YieldN/APrice Target$27.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Inhibikase Therapeutics alerts: Email Address Inhibikase Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,132.9% Upside$27.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.34Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.69) to ($1.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.39 out of 5 starsMedical Sector520th out of 938 stocksBiological Products, Except Diagnostic Industry84th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingInhibikase Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.00, Inhibikase Therapeutics has a forecasted upside of 1,132.9% from its current price of $2.19.Amount of Analyst CoverageInhibikase Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IKT. Previous Next 0.0 Dividend Strength Dividend YieldInhibikase Therapeutics does not currently pay a dividend.Dividend GrowthInhibikase Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IKT. Previous Next 2.4 News and Social Media Coverage News SentimentInhibikase Therapeutics has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Inhibikase Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for IKT on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.MarketBeat Follows3 people have added Inhibikase Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders20.30% of the stock of Inhibikase Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.81% of the stock of Inhibikase Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Inhibikase Therapeutics are expected to grow in the coming year, from ($3.69) to ($1.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibikase Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibikase Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInhibikase Therapeutics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Inhibikase Therapeutics Stock (NYSE:IKT)Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Read More IKT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IKT Stock News HeadlinesMarch 27, 2024 | globenewswire.comInhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent ActivityMarch 27, 2024 | americanbankingnews.comInhibikase Therapeutics (NYSE:IKT) Shares Up 3.6%March 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 7, 2024 | finance.yahoo.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological DisordersMarch 7, 2024 | globenewswire.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersMarch 7, 2024 | globenewswire.comInhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological DisordersMarch 6, 2024 | markets.businessinsider.comBuy Rating Backed by Promising Developments and Regulatory Confidence in Inhibikase’s PipelineMarch 5, 2024 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Inhibikase Therapeutics: Here's What You Need To KnowMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… February 28, 2024 | globenewswire.comInhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001ProFebruary 21, 2024 | markets.businessinsider.comInhibikase Therapeutics: Buy Rating Affirmed Amid Promising Drug Candidates and Strong Financial StandingFebruary 15, 2024 | finance.yahoo.comHere's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock NowFebruary 10, 2024 | investing.comInhibikase Therapeutics Inc (IKT)February 8, 2024 | msn.comInhibikase Discusses FDA Pathway for New Cancer DrugFebruary 7, 2024 | msn.comTenax Therapeutics, Equillium among healthcare moversFebruary 7, 2024 | finance.yahoo.comInhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal CancersFebruary 6, 2024 | msn.comNew Strong Buy Stocks for February 6thJanuary 29, 2024 | finance.yahoo.comInhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with RisvodetinibJanuary 22, 2024 | finance.yahoo.comInhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?January 17, 2024 | msn.comInhibikase Therapeutics appoints Lees-Rolfe as CFOJanuary 16, 2024 | finance.yahoo.comInhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph FrattaroliJanuary 5, 2024 | msn.comWhy Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving PremarketDecember 19, 2023 | finance.yahoo.comInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsDecember 15, 2023 | morningstar.comInhibikase Therapeutics Inc Ordinary SharesDecember 4, 2023 | markets.businessinsider.comInhibikase Therapeutics Gets FDA's Pre-NDA Meeting For IkT-001ProNovember 14, 2023 | seekingalpha.comInhibikase Therapeutics GAAP EPS of -$0.86November 13, 2023 | benzinga.comEarnings Preview For Inhibikase TherapeuticsSee More Headlines Receive IKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today3/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:IKT CUSIPN/A CIK1750149 Webwww.inhibikase.com Phone678-392-3419FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$27.00 High Stock Price Target$27.00 Low Stock Price Target$27.00 Potential Upside/Downside+1,073.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.9496) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,050,000.00 Net Margins-5,886.15% Pretax Margin-5,885.85% Return on Equity-94.66% Return on Assets-81.99% Debt Debt-to-Equity RatioN/A Current Ratio6.40 Quick Ratio6.40 Sales & Book Value Annual Sales$120,000.00 Price / Sales118.26 Cash FlowN/A Price / Cash FlowN/A Book Value$4.50 per share Price / Book0.51Miscellaneous Outstanding Shares6,170,000Free Float4,921,000Market Cap$14.19 million OptionableNot Optionable Beta1.19 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Milton H. Werner Ph.D. (Age 60)CEO, President & Director Comp: $658.19kMr. Joseph Frattaroli CPA (Age 62)Chief Financial Officer Comp: $531.83kDr. Roger RushHead of Preclinical ResearchDr. Surendra SinghHead of Chemistry, Manufacturing & ControlsDr. Charles Warren Olanow B.Sc.F.R.C.P.C., M.D., CEO of Clintrex Research Corporation & Member of Scientific Advisory BoardDan WilliamsControllerMore ExecutivesKey CompetitorsAcorda TherapeuticsNASDAQ:ACOREvaxion Biotech A/SNASDAQ:EVAXBioCardiaNASDAQ:BCDAOrganovoNASDAQ:ONVOGenetic TechnologiesNASDAQ:GENEView All CompetitorsInstitutional OwnershipVanguard Group Inc.Sold 5,402 shares on 3/11/2024Ownership: 1.330%Vanguard Group Inc.Sold 5,402 shares on 2/15/2024Ownership: 1.329%View All Institutional Transactions IKT Stock Analysis - Frequently Asked Questions Should I buy or sell Inhibikase Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inhibikase Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IKT shares. View IKT analyst ratings or view top-rated stocks. What is Inhibikase Therapeutics' stock price target for 2024? 1 analysts have issued 12-month price objectives for Inhibikase Therapeutics' stock. Their IKT share price targets range from $27.00 to $27.00. On average, they expect the company's stock price to reach $27.00 in the next year. This suggests a possible upside of 1,132.9% from the stock's current price. View analysts price targets for IKT or view top-rated stocks among Wall Street analysts. How have IKT shares performed in 2024? Inhibikase Therapeutics' stock was trading at $1.27 at the beginning of the year. Since then, IKT stock has increased by 72.4% and is now trading at $2.19. View the best growth stocks for 2024 here. When is Inhibikase Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our IKT earnings forecast. How were Inhibikase Therapeutics' earnings last quarter? Inhibikase Therapeutics, Inc. (NYSE:IKT) released its earnings results on Wednesday, March, 27th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.15. Inhibikase Therapeutics had a negative trailing twelve-month return on equity of 94.66% and a negative net margin of 5,886.15%. When did Inhibikase Therapeutics' stock split? Inhibikase Therapeutics's stock reverse split before market open on Friday, June 30th 2023. The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. When did Inhibikase Therapeutics IPO? Inhibikase Therapeutics (IKT) raised $15 million in an initial public offering on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. Who are Inhibikase Therapeutics' major shareholders? Inhibikase Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (1.33%) and Vanguard Group Inc. (1.33%). Insiders that own company stock include Joseph Frattaroli and Milton H Werner. View institutional ownership trends. How do I buy shares of Inhibikase Therapeutics? Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:IKT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.